Michael Kaseta
Known title: Chief Financial OfficerCIK: 0001724346
Michael Kaseta's purchase track record
How the stock did after each of Michael Kaseta's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
3
of 3 since May 31, 2022
Stock higher 6 months later
100%
3 months: 67%
Median 6-month return
+19.2%
3 months: +10.7%
Beat the S&P 500
100%
median +23.4% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 9/13/2022 | LQDA | $48K | +10.7% | +10.3% | -0.3% |
| 8/31/2022 | LQDA | $9K | -13.0% | +28.8% | -0.1% |
| 5/31/2022 | LQDA | $75K | +32.5% | +19.2% | -4.2% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
Heron Therapeutics Signs U.S. License Deal. Heron Therapeutics has entered a multi-product development and license agreement granting it exclusive rights to market products in the U.S. The company is obligated to pay milestone and royalty payments under this new arrangement. This development provides a potential pathway for future revenue, though the stock currently trades well below the average analyst target price.
Transaction History
| LQDA | ▼ Sell | Open Market | 1,453 | $104K | 7/13/2026 | View on chart |
| LQDA | ▼ Sell | Open Market | 18,977 | $1.4M | 7/13/2026 | View on chart |
| LQDA | ▲ Buy | Option Exercise | 5,829 | — | 7/10/2026 | View on chart |
| LQDA | ▲ Buy | Option Exercise | 7,050 | — | 7/10/2026 | View on chart |
| LQDA | ▲ Buy | Option Exercise | 86,971 | $243K | 4/15/2026 | View on chart |
| LQDA | ▼ Sell | Open Market | 86,971 | $3.5M | 4/15/2026 | View on chart |
| LQDA | ▼ Sell | Open Market | 43,375 | $1.7M | 4/15/2026 | View on chart |
| LQDA | ▼ Sell | Open Market | 9,044 | $363K | 4/15/2026 | View on chart |
| LQDA | ▲ Buy | Option Exercise | 3,000 | $8K | 4/14/2026 | View on chart |
| LQDA | ▼ Sell | Open Market | 3,000 | $120K | 4/14/2026 | View on chart |
| LQDA | ▼ Sell | Open Market | 18,958 | $727K | 4/13/2026 | View on chart |
| LQDA | ▼ Sell | Open Market | 23,821 | $956K | 4/10/2026 | View on chart |
| LQDA | ▲ Buy | Option Exercise | 7,050 | — | 4/10/2026 | View on chart |
| LQDA | ▲ Buy | Option Exercise | 23,821 | $66K | 4/10/2026 | View on chart |
| LQDA | ▲ Buy | Option Exercise | 5,828 | — | 4/10/2026 | View on chart |
| LQDA | ▲ Buy | Option Exercise | 19,042 | $53K | 4/9/2026 | View on chart |
| LQDA | ▲ Buy | Option Exercise | 86,632 | $242K | 4/9/2026 | View on chart |
| LQDA | ▲ Buy | Option Exercise | 18,115 | $54K | 4/9/2026 | View on chart |
| LQDA | ▲ Buy | Option Exercise | 9,272 | $24K | 4/9/2026 | View on chart |
| LQDA | ▼ Sell | Open Market | 133,789 | $5.4M | 4/9/2026 | View on chart |
| LQDA | ▲ Buy | Option Exercise | 728 | $2K | 4/9/2026 | View on chart |
| LQDA | ▼ Sell | Open Market | 1,165 | $36K | 3/2/2026 | View on chart |
| LQDA | ▲ Buy | Option Exercise | 2,344 | — | 2/27/2026 | View on chart |
| HRTX | ▲ Buy | Grant | 53,960 | $0 | 1/30/2026 | View on chart |
| LQDA | ▲ Buy | Grant | 59,320 | $0 | 1/16/2026 | View on chart |
| LQDA | ▼ Sell | Open Market | 36,932 | $1.4M | 1/12/2026 | View on chart |
| LQDA | ▲ Buy | Option Exercise | 5,828 | — | 1/9/2026 | View on chart |
| LQDA | ▲ Buy | Option Exercise | 28,200 | — | 1/9/2026 | View on chart |
| LQDA | ▼ Sell | Open Market | 1,166 | $38K | 12/1/2025 | View on chart |
| LQDA | ▲ Buy | Option Exercise | 2,343 | — | 11/28/2025 | View on chart |
| LQDA | ▼ Sell | Open Market | 11,630 | $272K | 10/13/2025 | View on chart |
| LQDA | ▲ Buy | Option Exercise | 5,828 | — | 10/10/2025 | View on chart |
| LQDA | ▼ Sell | Open Market | 1,148 | $33K | 9/2/2025 | View on chart |
| LQDA | ▲ Buy | Option Exercise | 2,344 | — | 8/29/2025 | View on chart |
| LQDA | ▼ Sell | Open Market | 20,000 | $524K | 8/15/2025 | View on chart |
| LQDA | ▼ Sell | Open Market | 30,000 | $600K | 8/5/2025 | View on chart |
| LQDA | ▼ Sell | Open Market | 11,580 | $165K | 7/14/2025 | View on chart |
| LQDA | ▲ Buy | Option Exercise | 5,828 | — | 7/11/2025 | View on chart |
| LQDA | ▼ Sell | Open Market | 14,777 | $251K | 6/4/2025 | View on chart |
| LQDA | ▲ Buy | Option Exercise | 29,141 | — | 6/3/2025 | View on chart |
| LQDA | ▼ Sell | Open Market | 859 | $14K | 6/2/2025 | View on chart |
| LQDA | ▲ Buy | Option Exercise | 2,344 | — | 5/30/2025 | View on chart |
| LQDA | ▼ Sell | Open Market | 8,283 | $112K | 4/14/2025 | View on chart |
| LQDA | ▼ Sell | Open Market | 874 | $14K | 3/3/2025 | View on chart |
| LQDA | ▲ Buy | Option Exercise | 2,344 | — | 2/28/2025 | View on chart |
| HRTX | ▲ Buy | Grant | 17,950 | $0 | 1/30/2025 | View on chart |
| LQDA | ▼ Sell | Open Market | 23,370 | $275K | 1/14/2025 | View on chart |
| LQDA | ▲ Buy | Grant | 112,797 | $0 | 1/11/2025 | View on chart |
| LQDA | ▼ Sell | Open Market | 1,091 | $13K | 12/2/2024 | View on chart |
| LQDA | ▲ Buy | Option Exercise | 2,343 | — | 11/30/2024 | View on chart |
| HRTX | ▲ Buy | Grant | 37,879 | — | 11/4/2024 | View on chart |
| LQDA | ▼ Sell | Open Market | 3,892 | $43K | 10/14/2024 | View on chart |
| LQDA | ▼ Sell | Open Market | 1,079 | $10K | 9/3/2024 | View on chart |
| LQDA | ▲ Buy | Option Exercise | 2,344 | — | 8/30/2024 | View on chart |
| LQDA | ▼ Sell | Open Market | 3,906 | $49K | 7/12/2024 | View on chart |
| LQDA | ▼ Sell | Open Market | 1,094 | $16K | 6/3/2024 | View on chart |
| LQDA | ▲ Buy | Option Exercise | 2,344 | — | 5/31/2024 | View on chart |
| LQDA | ▼ Sell | Open Market | 3,136 | $46K | 4/12/2024 | View on chart |
| LQDA | ▼ Sell | Open Market | 11,315 | $179K | 3/18/2024 | View on chart |
| LQDA | ▼ Sell | Open Market | 851 | $13K | 3/18/2024 | View on chart |
| LQDA | ▲ Buy | Option Exercise | 2,344 | — | 3/15/2024 | View on chart |
| LQDA | ▲ Buy | Grant | 50,000 | $0 | 1/15/2024 | View on chart |
| LQDA | ▲ Buy | Grant | 93,250 | $0 | 1/11/2024 | View on chart |
| LQDA | ▲ Buy | Option Exercise | 2,343 | — | 11/30/2023 | View on chart |
| LQDA | ▲ Buy | Option Exercise | 2,344 | — | 8/31/2023 | View on chart |
| LQDA | ▲ Buy | Option Exercise | 2,344 | — | 5/31/2023 | View on chart |
| LQDA | ▲ Buy | Option Exercise | 9,375 | — | 2/28/2023 | View on chart |
| LQDA | ▲ Buy | Grant | 124,667 | $0 | 1/11/2023 | View on chart |
| LQDA | ▲ Buy | Open Market | 8,000 | $48K | 9/13/2022 | View on chart |
| LQDA | ▲ Buy | Open Market | 1,927 | $9K | 8/31/2022 | View on chart |
| LQDA | ▲ Buy | Open Market | 13,639 | $55K | 5/31/2022 | View on chart |
| LQDA | ▲ Buy | Open Market | 5,061 | $20K | 5/31/2022 | View on chart |
| LQDA | ▲ Buy | Option Exercise | 9,250 | — | 11/10/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 7, 2026
Liquidia shares fall on patent court loss and analyst downgrades
Liquidia stock is down sharply after a court ruling regarding YUTREPIA patent access, which analysts say clouds the drug's future. Wells Fargo downgraded the stock to Equal-Weight and lowered its price target to $30, while other analysts also cut their targets. The stock is currently trading near its 52-week low, reflecting significant market concern over the legal outcome.
Liquidia shares fall on patent court loss and analyst downgrades. Liquidia stock is down sharply after a court ruling regarding YUTREPIA patent access, which analysts say clouds the drug's future. Wells Fargo downgraded the stock to Equal-Weight and lowered its price target to $30, while other analysts also cut their targets. The stock is currently trading near its 52-week low, reflecting significant market concern over the legal outcome.